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ABSTRACT 
 The new gene editing system CRISPR/Cas9, composed of a complex 
composed of a guide RNA and the Cas9 endonuclease, promises to revolutionize 
biological research and potentially allow clinicians to directly modify patient DNA in 
vivo. While its applications in the treatment of genetic diseases and in modifying 
immune cells for immunotherapy are currently being explored, CRISPR/Cas9’s 
potential utility as a modular system for targeting tumor-specific mutated 
sequences has not as of yet been explored. While CRISPR/Cas9 is specific enough to 
target small insertions and deletions or gross chromosomal rearrangements, it is 
not specific enough to reliably restrict editing to single nucleotide variants (SNVs), 
which compose the majority of cancer-associated mutations. By searching for 
tumor-specific SNVs that generate new protospacer adjacent motifs (neoPAMs), a 
short sequence that must be present next to the target sequence in order for Cas9 to 
cleave at the target site, gene editing can theoretically be restricted to tumor cells 
bearing the mutation of interest. This capability could permit the insertion of suicide 
genes, pro-inflammatory cytokines, or immunogenic epitopes in a tumor-specific 
manner. The results shown here demonstrate the importance of taking into account 
guide RNA efficiency when selecting a target site. New target sites in the tumor cell 
line FABF with high predicted guide RNA efficiencies are identified and discussed. 
Finally, strategies for maximizing the antitumor effect of neoPAM-restricted gene 
editing are described and compared. 
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INTRODUCTION 
 Tumors contain, and are driven by, somatic mutations1. Chief among these 
are the single nucleotide variations (SNVs), point mutations found in all known 
human cancers1,2. While some somatic mutations are acquired later in neoplastic 
development and hence are not shared by all cancer cells in a tumor (the so-called 
branch mutations), a subset are acquired before or during the process of neoplastic 
transformation and hence are shared by almost all cancer cells (the so-called trunk 
mutations)3. These trunk mutations are unique identifiers of tumor cells, but no 
methods are presently available to use trunk mutations as a basis to therapeutically 
target tumor cells for destruction. 
 Sequence-specific gene editing may potentially allow such a capability. 
Nucleases such as zinc-finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) provide sufficient sequence specificity to in theory 
permit the selective modification of cancer-specific mutated sequences, but 
inefficiencies in nuclease design and production have severely limited their use in a 
clinically relevant context4,5. The new CRISPR/Cas9 gene editing system is both 
more efficient and far easier to use than these older systems, and hence may soon be 
widely employed in human therapeutic gene editing6-8. 
 Two RNA molecules, the CRISPR RNA (crRNA) and trans-acting CRISPR RNA 
(tracrRNA) interact to form the complete guide RNA (gRNA) molecule. The gRNA 
then forms a complex with the Cas9 endonuclease to form the complete Cas9 
ribonucleoprotein (Cas9 RNP). Biochemical manipulations permit the use of a single 
guide RNA (sgRNA) composed of a single sequence that folds on itself to mimic the 
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crRNA:tracrRNA interaction, vastly simplifying gene editing6-9. The approximately 
20 nucleotides at the 5’ end of the gRNA restrict the nuclease activity of Cas9 to 
target DNA with sufficient sequence complementary as determined by Watson-Crick 
base pairing8,9. Sequence complementarity is insufficient to mediate double-
stranded break (DSB) induction, however - a short motif, called a protospacer 
adjacent motif (PAM), must be present immediately next to the target sequence to 
permit nuclease activity8,9. The canonical PAM of the most commonly used Cas9 
isoform from Streptococcus pyogenes (SpCas9) is 5’-NGG-3’, where N can be any 
nucleotide6-9. A guanine in the first position is generally preferred, but not strictly 
required10. 
 The specificity of wild-type Cas9 is not perfect – mismatches between the 
target sequence and gRNA are sometimes tolerated6,7. PAM proximal mismatches 
and strings of mismatches are not well tolerated, while isolated, PAM distal 
mutations do not often affect Cas9 activity10-12. Further, off-target PAM sequences 
have been observed for wild-type SpCas9, with 5’-NAG-3’ constituting the vast 
majority of the off-target PAM sequences10,11. 
 The Cas9-induced DSB can be repaired via two main pathways. The first is 
error-prone non-homologous end joining (NHEJ) whereby the blunt ends of the DNA 
are directly ligated together, often generating gene-inactivating small insertions and 
deletions (indels)6,8,9. Alternatively, DSBs may be repaired by homology-directed 
repair (HDR) whereby a DNA strand homologous to the damaged strand is used as a 
template for precise repair. Transfection with exogenous DNA sequences containing 
homology arms at the 5’ and 3’ ends matching either side of the Cas9 target site 
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permits the insertion, mediated by HDR, of virtually any DNA sequence at any locus 
with high fidelity6,8,9. 
 Multiple groups have made modifications to SpCas9 to enhance its specificity 
and versatility. Foremost among these are the nickases and nuclease-null variants, 
which knock out either one or both of the catalytic subunits responsible for strand 
breakage respectively13. Single or paired nickases can be used to generate either 
single-stranded breaks (SSBs) or DSBs with large overhangs, which both severely 
limit the frequency of NHEJ and thereby bias editing towards HDR14,15. Further, 
nuclease-null variants, referred to as dead Cas9 or dCas9, can be used to activate or 
repress transcription or visualize genomic loci16,17. Other groups have rationally 
modified SpCas9 to limit its non-specific contacts with DNA, thereby improving its 
specificity18,19. Finally, recent work has shown that the use of truncated guide RNAs 
can significantly reduce off-target DSB events without sacrificing on-target 
activity20. Sufficiently truncating the guide RNA can eliminate DSB induction without 
interfering with Cas9’s ability to bind target sites, permitting multiplexed gene 
editing and transcriptional modulation from the same protein21. 
 Recent work has shown that an SNP that generates a novel PAM sequence 
can restrict Cas9-mediated gene editing to the SNP-containing chromosome, with no 
detectable off-target editing at the other chromosome22. This suggests a cancer-
specific point mutation that generates a new PAM, a neoPAM, can restrict Cas9-
mediated genome editing to cancer cells alone. While the target sequence 
complementary to the gRNA would be present with zero mismatches in both tumor 
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and healthy tissue, only tumor cells would have the necessary adjacent neoPAM 
sequence to permit recognition and DSB induction by Cas9. 
 The cancer-specific DSB generated by neoPAM restriction can be used to 
mediate the insertion of new genes via HDR. Even if neoPAM restriction is truly 
tumor-specific, it is unlikely that all cancer cells will be targeted due to the low 
efficiencies of in vivo delivery and HDR23,24. Cytotoxic elements that exert potent 
bystander effects whereby successfully transformed tumor cells induce cell death or 
growth inhibition in nearby cells may solve this problem. One well-studied class of 
genes that carry this property is the suicide genes. These genes convert non-toxic 
prodrugs to toxic metabolites, and their selective expression in cancer cells permits 
tumor-specific cytotoxicity25-28. The best studied of these are the herpes simplex 
virus thymidine kinase/ganciclovir (HSV-TK/GCV) and cytosine deaminase/5-
fluorocytosine (CD/5-FC) systems, though other effective systems exist28. 
 In the HSV-TK/GCV system, the thymidine kinase from herpes simplex virus 
monophosphorylates nucleoside analogs like ganciclovir, an analog of 2’-
deoxyguanosine bound to an acyclic sugar. The monophosphorylated intermediate 
is fully phosphorylated by endogenous enzymes and incorporated into DNA by 
endogenous polymerases, whereupon its incomplete sugar ring induces termination 
of chain elongation and eventually cell death through ligand-independent death 
receptor aggregation and subsequent apoptosis29-31. Because ganciclovir 
triphosphate is triply negatively charged, it cannot diffuse across cell membranes 
and hence relies on gap junctions to exert a bystander effect32. In tumor cells that 
Englander   11 
are gap junction deficient, the bystander effect of the HSV-TK/GCV system can be 
restored through pharmacological induction of gap junctions35. 
 Multiple attempts have been made to modify the HSV-TK enzyme to both 
increase its sensitivity to ganciclovir and reduce its affinity for its intended 
substrate29. These efforts have produced mutants that dramatically increase 
transduced tumor cell sensitivity to ganciclovir, occasionally by over two orders of 
magnitude34. One rationally designed mutant in particular, TK007, introduces a 
targeted A to H mutation at position 168 that markedly reduces the enzyme’s 
affinity for deoxythymidine while retaining its affinity for ganciclovir, thereby 
enhancing its efficiency35. This modification dramatically improves TK007’s killing 
efficiency and its bystander effect both in vitro and in vivo in a murine xenograft 
model36. 
 The CD/5-FC system uses cytosine deaminase from either E. coli or S. 
cerevisiae to convert the nontoxic prodrug 5-fluorocytosine into the widely used 
chemotherapeutic 5-fluorouracil (5-FU). 5-FU is readily converted in situ by 
endogenous enzymes to its monophosphorylated form 5-fluoro-2’-deoxyuridine-5’-
monophosphate (5-FdUMP) which irreversibly inhibits the essential enzyme 
thymidylate synthetase or to its triphosphorylated form 5-fluorouridine-5’-
triphosphate which can be incorporated into RNA and subsequently inhibits nuclear 
RNA processing28. While these phosphorylated molecules are restricted to the cells 
in which they were produced, 5-FU can freely diffuse across cell membranes due to 
its neutral charge and small size. Thus, the CD/5-FU system mediates a significantly 
more potent bystander effect than the HSV-TK/GCV system37. Further, yeast CD, 
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which has a significantly lower Km value for 5-FC than bacterial CD, is a far smaller 
gene than either HSV-TK or bacterial CD28,38. 
 Both of these systems are somewhat limited in that the suicide enzyme is 
localized to successfully transduced tumor cells. Intercellular trafficking 
mechanisms by which the enzymes could be transferred between neighboring cells 
after expression have the potential to markedly increase the efficacy of these 
systems. One such modification, a fusion of the viral intercellular trafficking protein 
VP22 to HSV-TK, permitted the transfer of the fusion protein from a donor 
transfected cell line to co-cultured gap junction-negative neuroblastoma cells, 
mediating extensive cell death in this untransfected, bystander effect-impaired cell 
line39. This fusion protein was later demonstrated to modestly increase sensitivity 
to ganciclovir in a human epithelial cell line40. A similar fusion protein was 
constructed using bacterial CD that also mediated increased sensitivity to its 
prodrug substrate compared to its wild type counterpart41. 
 In contrast to gene therapy strategies that rely on enzymes and their 
cytotoxic metabolites to mediate tumor cell death, tumor-targeted immune gene 
therapies modify tumor cells to express cytokines or ligands that stimulate an 
antitumor immune response42. These techniques can initiate a new immune 
response against tumor-associated antigens or can help overcome tumor-mediated 
immunosuppression. The stunning effectiveness of immune checkpoint blockade 
supports the notion of leveraging the immune system to fight cancer. These 
antibody-based therapeutics function by unleashing preexisting immune responses 
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against tumor neoantigens, lending support to the notion that enhancing tumor 
immunogenicity through gene therapy may be an effective therapeutic modality43-46. 
 The earliest studies into immunoactivatory gene therapy focused on the 
transfection of inflammatory Th1 cytokines known to be crucial to the adaptive 
antitumor immune response. The most prominent of these cytokines are 
interleukin-2 (IL-2) and interferon-γ. IL-2 is essential for CD8+ and CD4+ T cell 
proliferation, differentiation, and effector function acquisition47,48. The acquisition 
of effector functions in vitro impairs IL-2 secretion and limits a sustained antitumor 
immune response in vivo49, while IL-2 secretion by tumor cells overcomes the need 
for CD4+ T cell help in the generation of an MHC I-restricted, cytotoxic lymphocyte 
(CTL)-mediated antitumor response50. In a murine fibrosarcoma model, IL-2 
secretion by CMS-5 tumor cells induced a CTL response against both the parental 
and IL-2 secreting cell lines. Mice that rejected IL-2 secreting CMS-5 were protected 
against rechallenge with a tumorigenic dose of parental CMS-5, indicating the 
antitumor immune response was specific for tumor antigens51. These results have 
relevance for human patients, as immunization of neuroblastoma-bearing children 
with autologous unirradiated tumor cells transduced with adenoviral DNA 
expressing IL-2 magnified CTL killing of autologous tumor cells and generated a 
local CD4+ helper cell-mediated inflammatory environment52. IL-2, while clearly 
beneficial for the establishment and maintenance of an antitumor immune response, 
is also responsible for the activation and expansion of powerfully 
immunosuppressive T regulatory cells (Tregs) in response to self-antigen53,54. Treg 
activity and induction from naïve CD4+ T cells are known to be key mechanisms by 
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which tumors escape the immune response55,56, and hence IL-2 secretion by tumor 
cells is unlikely to be broadly sufficient for immune-mediated tumor rejection. 
Interferon-γ, meanwhile, is crucial for cellular immunity and hence has a central 
role in immune-mediated tumor control57. It is secreted by activated NK, NKT, Th1 
helper cells, and CTLs and has a broad array of functions, including inducing MHC 
Class I and Class II expression, promoting a Th1 cell phenotype, activating resident 
macrophages, promoting tumor cell apoptosis and the release of pro-inflammatory 
cytokines, and inhibiting angiogenesis57-65. It has been shown to augment the 
expression of viral antigens in the nonimmunogenic sarcoma MCA 101, thereby 
aiding in the generation of tumor-specific CTLs66. Further, interferon-γ may be 
involved in the suppression of Treg proliferation mediated in part by interleukin-12 
(IL-12), a cytokine secreted by activated Th1 and NK cells67, potentially limiting 
Treg expansion driven by IL-2. These results provide a strong rationale for in vivo 
tumor modification to induce intratumoral secretion of both interferon-γ and IL-2. 
 Other cytokines, in particular tumor necrosis factor, interferon-α, and IL-12, 
are intimately involved in the antitumor innate and adaptive immune responses to 
varying degrees68-76. Thus, immunoactivatory in vivo tumor gene modification 
strategies may also induce the secretion of these cytokines either in combination 
with interferon-γ, IL-2, and/or each other. However, as homologous recombination 
efficiency decreases with increasing insert size77, the additional efficacy associated 
with the expression of additional cytokines would need to be balanced against the 
decreased number of successfully transformed cancer cells. 
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 A number of immunoactivatory ligands can also be used to enhance the 
immunogenicity of tumors. Co-stimulatory ligands, namely B7-1, B7-2, and B7h, are 
expressed on activated antigen-presenting cells (APCs) and bind either CD28 (in the 
case of B7-1 and B7-2) or ICOS (in the case of B7h) on T cells. The CD28-B7 
interaction is a necessary costimulatory signal for T cell activation; without it, TCR 
engagement with the target peptide-MHC complex leads to anergy instead of 
activation78-81. Hence, a paucity of costimulatory B7 expression on APCs may impair 
the antitumor immune response by preventing T cell priming. In a variety of tumor 
models, transfection of tumor cells with B7-1 or B7-2 leads to the activation of CD8+ 
and/or CD4+ T cell responses that can eradicate established tumors and provide 
protection against the parental tumor cell line82-84. Hence, selective in vivo 
modification to induce costimulatory ligand expression in tumor cells either alone 
or in combination with pro-inflammatory cytokines may have clinical relevance. 
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MATERIALS AND METHODS 
 Identification of FABF-specific neoPAMs – The murine tumor cell line FABF, a 
cell line identified in the Srivastava lab, was used for the following studies. The FABF 
exome had been sequenced previously and the data generously provided by Cory 
Brennick. A program was written to identify point mutations that produced GG or 
CC dinucleotides excluding GG dinucleotides where the wild type sequence was 5’-
AG-3’ or CC dinucleotides where the wild type sequence was 5’-CT-3’. If the 
mutation produced a GG dinucleotide, the putative target sequence was retrieved 
from the 21 nucleotides 5’ of the dinucleotide on sense strand in the UCSC Mus 
musculus version mm10 reference genome. The first 20 nucleotides of this sequence 
were converted to the corresponding RNA sequence and ordered as an sgRNA from 
Sigma Aldrich. In contrast, if the mutation produced a CC dinucleotide, the putative 
target sequence was retrieved by reconstructing the antisense strand from the 21 
nucleotides 3’ of the dinucleotide in the mm10 reference genome85. 
 NeoPAM efficiency screen – The cleavage efficiency of putative sgRNAs was 
predicted with the online CRISPR Efficiency Predictor tool. Any putative sgRNA with 
a score above 7.5 were considered fit for further analysis. 
 Design and synthesis of donor DNA – The 500 nucleotides 5’ and 3’ of the 
chosen target site were obtained from the mm10 reference genome85. The minimal 
cytomegalovirus early/intermediate enhancer and promoter elements were 
obtained from the sequence data of Plasmid #80802 in the Addgene database86. The 
SV40 polyadenylation signal was obtained from the sequence data of Plasmid 
#55764 in the Addgene database87. The chicken ovalbumin sequence was retrieved 
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from entry P01012 in the Uniprot database88. Finally, an ER insertion sequence was 
retrieved from the literature89. Donor DNA sequences were constructed in silico, 
synthesized by GenScript, and quantified by a NanoDrop spectrophotometer. 
 Cell culture – FABF cells were grown in RPMI (Life Technologies) 
supplemented with 10% heat-shocked fetal bovine serum, penicillin/streptomycin, 
sodium pyruvate, non-essential amino acids, and β-mercaptoethanol (complete 
RPMI). Cells were grown until they became 90% confluent, after which they were 
trypsinized and either used in downstream applications or seeded into larger flasks. 
When stocks needed to be made, cells were resuspended to between 2*106 and 
8*106 cells/mL in complete RPMI supplemented with an additional 10% heat-
shocked fetal bovine serum and 10% DMSO and stored in cryopreservation tubes at 
-80 °C. Cells were thawed by placing the cryopreservation tubes in a 37 °C water 
bath for 1 minute or until fully thawed directly from the -80 °C freezer. 
 Cas9 RNP transfection – Lipofectamine CRISPRMAX (Thermofisher) was used 
for all transfections. Manufacturer protocols were modified as follows: one day 
before transfection, 5*104 FABF cells were seeded in the requisite number of wells 
of a 24 well plate in 500 μL complete RPMI media such that the plates were between 
30% and 70% confluent at the time of transfection. On the day of transfection, Cas9 
v2 protein (ThermoFisher Scientific), sgRNA (Sigma Aldrich, custom synthesized), 
and donor DNA (GenScript, custom synthesized) were thawed on ice. Opti-MEM 
reduced serum media, Cas9 Plus reagent, and Lipofectamine CRISPRMAX (all 
ThermoFisher Scientific) were moved from 4 °C and kept on ice until use. 25 μL of 
Opti-MEM media was then added to two sterile Eppendorf tubes. 1250 ng Cas9 v2 
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protein and 240 ng sgRNA were added to one of these tubes (Tube 1) while 
concurrently 1.5 μL of Lipofectamine CRISPRMAX was added to the second tube 
(Tube 2). Both of these tubes were briefly vortexed and 1 μL of Cas9 Plus reagent 
was added to Tube 1. Both tubes were incubated at room temperature for 5 
minutes, after which 300 ng of linear donor DNA was added to Tube 1. Tube 1 was 
then briefly vortexed and its contents added to Tube 2, which was then vortexed 
briefly and incubated at room temperature for 15 minutes. 50 μL of this mixture was 
then added to the cells in a single well and mixed well. Cells were incubated for 1 
day before the addition of an additional 750 μL of complete RPMI. On the second day 
after transfection, media was removed, wells were washed with 1 mL PBS twice, and 
500 μL of 37 °C of trypsin EDTA was added to each well and allowed to incubate at 
37 °C for approximately 1 minute. Wells were then washed with 2 mL complete 
RPMI and transferred to 14 mL Eppendorf tubes. The tubes were then diluted with 
10-14 mL complete RPMI and spun down at 300 g for 5 minutes, resuspended with 
10 mL complete RPMI, and plated. 
 sgRNA cleavage validation assay – Approximately 1*106 cells were lysed and 
digested with Cell Lysis Buffer and Protein Degrader from the GeneArt® Genomic 
Cleavage Detection Kit (Thermofisher). 2 μL of cell lysate was added to a PCR 
reaction with 0.2 μM of each primer and the PCR master mix provided by the 
Cleavage Detection Kit according to manufacturer protocols and cycled as follows: 
10 min. @ 95 °C, 1 cycle; 30 sec. @ 95 °C and 30 sec. at the lowest primer Tm – 5 °C 
and 30 sec. at 72 °C, 40 cycles; 7 min. at 72 °C, 1 cycle; 4 °C hold. The PCR product 
was concentrated and contaminating proteins and chaotropic salts removed with 
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the PCR Clean-Up and Gel Extraction Kit (Takara Bio) according to manufacturer 
protocols. Purified PCR product was quantified with a NanoDrop 
spectrophotometer. 100 ng of DNA was then denatured, re-annealed, and digested 
according to manufacturer protocols. 10 μL of the resulting solution was run on a 
2% agarose gel at 50 V for 1 hour and visualized with a GelDoc imager (Bio-Rad 
Laboratories). 
 B3Z coculture assay – FABF cells were trypsinized, resuspended, and counted 
with an automatic hemocytometer and AO/PI staining according to standard 
protocols. 200,000 FABF cells per group were then added to a 96 well round bottom 
plate in 100 μL of complete RPMI. Semi-adherent B3Z cells were then resuspended 
and counted via AO/PI staining with an automatic hemocytometer. 200,000 B3Z 
cells were then added to the plates previously seeded with FABF in 100 μL of 
complete RPMI such that each well contained 200 μL of media. Plates were 
incubated at 37 °C for 20 hours. Plates were then spun at 931 g for 2 min and the 
supernatant was decanted. Wells were gently washed twice with 200 μL PBS such 
that the cells at the bottom of the well were not disturbed. 150 μL of a pre-prepared 
solution of chlorophenol red-β-D-galactopyranoside (45.5 mg chlorophenol red-β-
D-galactopyranoside, 2.5 mL NP40, and 4.5 mL of 1 M MgCl2 in 500 mL of PBS) was 
then added to each well and allowed to incubate at room temperature for 15 
minutes. Each well was gently resuspended, avoiding the creation of air bubbles, 
and 120 μL was transferred from each well to one of the wells of a 96 well flat 
bottom plate. This plate was then incubated at 37 °C for 1 hour. This plate was then 
transferred to a dark place shielded from light and incubated at room temperature 
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for 24 hours. The plate was then read at 570 nm on an iMark microplate reader 
(Bio-Rad Laboratories). 
 Peptide pulsing – 800,000 FABF cells were resuspended in 500 μL and pulsed 
with either 1 or 10 μM of the peptide SIINFEKL in DMSO for one hour at 37 °C. After 
pulsing, cells were washed three times with 10 mL of PBS. 
 Crude DNA extraction and PCR – 700,000 FABF cells were resuspended in 180 
μL of 50 mM NaOH and moved into a PCR tube which was then incubated at 95 °C 
for 10 minutes. 25 μL of 1 M Tris-HCl was then added to neutralize the solution. 5 μL 
of this lysate was added to a Terra™ Direct Red Dye Premix (Takara Bio) reaction 
with a 0.5 μM of each primer according to manufacturer recommendations. For 
positive controls, the higher volume of either 10 ng of DNA or 0.1 μL of stock 
solution was mixed in a Terra™ Direct Red Dye Premix reaction according to 
manufacturer protocols with 0.5 μM of each primer. The reactions were held in hot 
start mode for 10 minutes and subsequently cycled as follows: 2 min. @ 98  °C, 1 
cycle; 10 sec. @ 98  °C and 15 sec. @ 56 °C and 2:30 @ 68 °C, 30 cycles; 4 °C hold. 5 
μL of each reaction was then run on a gel with an agarose quantity sufficient to 
resolve bands of the expected size(s) at 90 V for an hour. 
 High quality DNA extraction and PCR – The DNA of between 1*106 and 2*106 
FABF cells was extracted with a DNeasy® Blood and Tissue Kit (Qiagen) according to 
manufacturer protocols. The quantity of DNA was measured using a NanoDrop 
spectrophotometer. 400 ng of extracted genomic DNA or 10 ng of purified plasmid 
DNA was mixed with 0.5 μM of each primer and the remaining PCR components 
according to established Long Amplification AccuTaq manufacturer protocols 
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(Sigma Aldrich). Annealing temperatures were set at 5 °C below the lowest 
annealing temperature for any given set of reactions. The reactions were then cycled 
as follows: 2 min @ 98  °C, 1 cycle; 10 sec @ 96  °C and 15 sec @ annealing 
temperature and 2:30 @ 68 °C, 30 cycles; 4 °C hold, indefinitely. 5 μL of each 
reaction was then mixed with 5 μL of loading buffer and run on a gel with an 
agarose quantity sufficient to resolve bands of the expected size(s) at 90 V for an 
hour. 
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RESULTS 
 
 Figure 1: Strategy for Tumor-Specific Gene Insertion. In normal tissue, 
the sgRNA-Cas9 complex cannot cleave the target sequence because there is no PAM 
immediately 3’ of the target site in the genomic DNA. In contrast, a tumor-specific 
mutation creates a neoPAM immediately 3’ of the target site, allowing the same 
sgRNA-Cas9 complex to cleave the DNA and generate a DSB. An exogenous donor 
DNA sequence flanked with arms of homology to either side of the Cas9-generated 
DSB is used by the cell as a template for repair via homologous recombination, 
thereby precisely inserting the exogenous DNA into the malignant cell at the target 
locus. Of the available target sites, Target Sequence 17 (Target17) was chosen 
because of its low predicted levels of off-target effects (data not shown). 
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 Figure 2: Composition of Donor DNA Constructs. Three different donor 
DNA constructs were designed and synthesized to identify an expression strategy 
that would maximize the expression of SIINFEKL, an immunogenic peptide from 
chicken ovalbumin that is recognized by a wide variety of well-characterized T cell 
hybridomas89-91. SIINFEKL was chosen as a model antigen because the wide array of 
SIINFEKL-specific hybridomas and transgenic T cell lines makes the detection of 
SIINFEKL expression in an immunologically relevant context methodologically 
simple90,91. 
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 In each construct, homology arms obtained from the sequences surrounding 
the sgRNA target site flank the minimal cytomegalovirus early/intermediate 
enhancer/promoter element and the SV40 polyadenylation signal. In the ER Insert 
sequence, the ER insertion signal from the E3/19K adenovirus protein was attached 
to the N-terminus of SIINFEKL to promote the insertion of the recombinant 
polypeptide into the ER where MHC Class I loading occurs and thereby enhance 
loading of SIINFEKL onto MHC Class I92,93. The ER insertion signal is not required for 
peptide loading onto MHC Class I, as in its absence cytosolic peptide will be 
transported to the lumen of the ER by the transporter associated with antigen 
processing (TAP)94. In the Spacers sequence, the 15 amino acids N-terminal to 
SIINFEKL and 11 amino acids C-terminal to SIINFEKL from the endogenous 
ovalbumin sequence were included in the minigene sequence to account for the 
possibility that the flanking sequences assist in peptide processing. Finally, the 
TruncOVA sequence is a truncated ovalbumin sequence without the first 100 amino 
acids. This polypeptide will not fold and will be degraded, releasing SIINFEKL into 
the cytosol where it should be transported into the ER, loaded on MHC Class I, and 
presented on the cell surface. 
 
 
 
 
 
 
Englander   25 
(a) 
 
 
(b)  
 
 Figure 3: No Donor DNA Construct Drives SIINFEKL Presentation. (a) 
B3Z, a T cell hybridoma specific for SIINFEKL that produces LacZ upon TCR 
engagement90, was cocultured with FABF cells transfected two days prior with 
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Target17 sgRNA, Cas9, and the indicated donor DNA constructs. Negative controls 
were FABF cells transfected with donor DNA alone. Naïve FABF was also pulsed 
with SIINFEKL and cocultured with B3Z cells as a positive control as tumor cells will 
take up peptide from the medium and present it on MHC Class I94. After a day of 
coculture, cells were lysed and the lysate incubated with CRPG, a yellow compound 
that is a substrate for β-galactosidase. CRPG turns red after cleavage by β-
galactosidase, allowing detection of LacZ expression and hence TCR engagement by 
measuring the lysate’s absorbance at 570 nm. While TruncOVA produced what 
appears to be a moderate positive signal, its corresponding negative control group’s 
signal is higher. To account for the possibility the negative control group’s signal 
was artifactual, this experiment was repeated. (b) The same experiment as in (a) 
except only TruncOVA was included in the assay and both the negative control and 
experimental groups were assayed in five replicates. SIINFEKL-pulsed and naïve 
FABF were only assayed in one replicate each. No signal was detected in either the 
TruncOVA negative control or experimental group, demonstrating that the signal 
seen in (a) was artifactual and no donor DNA constructs drive the presentation of 
SIINFEKL at the FABF cell surface. 
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(a) 
  
 
(b) 
  
 Figure 4: NeoPAM Knock-In with Target17 Does Not Mediate Construct 
Insertion at the Target Site. (a) A lack of presentation could have been because of 
no construct insertion, no expression, or a defect in presentation. To identify which 
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of these was the cause of the negative results in Figure 3, the homology arms 
included in the donor DNA constructs were amplified from crude extract of ER 
Insert, Spacers, and TruncOVA negative controls and experimental groups and from 
purified donor DNA as a positive control. Since the homology arms are present in 
both the donor DNA and FABF itself, amplification was expected to occur regardless 
of the success of construct insertion. No insertion was expected to produce a 927 bp 
band (black arrows), while insertion of ER Insert, Spacers, or TruncOVA was 
expected to produce a 1623 bp band (blue arrow), a 1650 bp band (green arrow), or 
a 2412 bp band (red arrow), respectively. In both the negative controls and 
experimental groups for each individual construct, no band above 927 bp in size can 
be detected, while positive controls produce bands of the expected size. Nonspecific 
bands are likely due to the crude extract and hypersensitive polymerase used for 
these experiments. (Lanes 1, 2, 3: ER Insert, Spacers, and TruncOVA negative 
controls, respectively; Lanes 4, 5, 6: ER Insert, Spacers, and TruncOVA experimental 
groups, respectively; Lanes 7, 8, 9) (b) To ensure that small amounts of inserted 
construct was not outcompeted by the more numerous endogenous sequence for 
polymerase, primers were designed to amplify from the 3’ end of the CMV promoter 
to the 5’ end of the SV40 polyadenylation signal. Because this sequence is only 
present in the donor DNA, successful amplification from FABF genomic DNA could 
only occur if the donor DNA construct was successfully inserted. No bands were 
observed for both the negative controls and experimental groups for each individual 
construct. In contrast, bands of 341 bp (blue arrow), 368 bp (green arrow), and 
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1130 bp (red arrow) are observed for amplification with ER Insert, Spacers, and 
TruncOVA donor DNA as template, respectively. 
 Figure 5: Target17 Is an Inefficient sgRNA. The Surveyor nuclease cleaves 
mismatched DNA, allowing quantification of the proportion of indels produced by 
Cas9 cleavage at a given target site95,96. The Target17 target site was PCR amplified 
and digested with the Surveyor nuclease. A distinct, smaller band alongside the 
parental band therefore indicates the presence of indels produced by Cas9-
mediated target site cleavage. Greater intensity of the band representing the smaller 
cleavage product indicates higher sgRNA efficiency. No band indicative of cleavage 
by the Surveyor nuclease was observed in either a mock transfected control or FABF 
cells transfected with Cas9 and Target17. A smaller band indicative of cleavage 
(purple arrow) was observed in a positive control that came with the Surveyor 
nuclease kit. Taken together, these results demonstrate that Target17 is an 
inefficient sgRNA that does not significantly cleave its target site. Further, this result 
explains why no insertion was observed at the target site – without target site 
cleavage, the donor DNA cannot be used as a template for homology-directed repair. 
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Identifier Wild 
Type 
PAM 
NeoPAM Target Sequence Predicted 
Efficiency 
TARGETSEQUENCE122 CAG CGG CAAGTTCAACGTGTGGGACA 9.0919 
TARGETSEQUENCE11 AGA AGG GAGGCCAGCCTGGTCTATAG 9.07017 
TARGETSEQUENCE29 TAG TGG CATCGCCAACTTCTCTGAGC 8.96595 
TARGETSEQUENCE47 TGA TGG TCATGCAGGCATCCGACGAG 8.90553 
TARGETSEQUENCE8 TTG TGG TCTCTATACCACTTCTCTAC 8.70791 
TARGETSEQUENCE97 GAG GGG CGGCTGCGGCGAGCGGGGAG 8.67553 
TARGETSEQUENCE209 GGT GGG TGCCGGCGACGGCTGGGTAT 8.61632 
TARGETSEQUENCE15 CCG CGG AGAGTCCTGCCGCTTCAAGG 8.55223 
TARGETSEQUENCE202 TGC TGG GTCCAAGAGCATGCAGTGAC 8.42117 
TARGETSEQUENCE60 CGA CGG TTCTGGGGTCTGATGAGCGT 8.25255 
TARGETSEQUENCE172 CTG CGG GTTTCCCGGAAGCTGCCCGG 8.17607 
TARGETSEQUENCE134 TTG TGG TGATGTTTCCAGTTATTTAT 8.15388 
TARGETSEQUENCE87 CTG CGG GGCGTCCCGCGGGCCGGCGC 8.14489 
TARGETSEQUENCE115 GGC GGG TGGAGGCTGCACAGTGCACA 8.12777 
TARGETSEQUENCE113 GTG GGG TTTTTTTGGTGTGTGTGTGT 8.10467 
TARGETSEQUENCE61 TTG TGG CTATGCTTACTGTTCTGTTT 8.08406 
TARGETSEQUENCE64 TGC TGG TGAAGAGGTCGTGGGGAATG 7.98259 
TARGETSEQUENCE168 CAG CGG ATTCCCAAGCAATCCGACTC 7.97552 
TARGETSEQUENCE111 AGA AGG GGAGCCTTCCTCTTTCTGTT 7.90524 
TARGETSEQUENCE31 CAG CGG CCAGGACTGAGCCTGGGGAC 7.90438 
TARGETSEQUENCE25 CAG CGG ACATCCATGGAGCTGTCAGC 7.88473 
TARGETSEQUENCE152 AGC CGG ACAGGGAAGTGCCTGTCGTG 7.82484 
TARGETSEQUENCE138 CTG CGG CGCCAGAAGCGAGAGCCCCT 7.8206 
TARGETSEQUENCE46 CAG CGG GCAGTTAAACATGGGTCAGT 7.78494 
TARGETSEQUENCE114 AGA AGG CTTTCAGAACGGGACCGCCG 7.59664 
TARGETSEQUENCE49 CGC CGG GGTGGAAGGCCACGAGCGCT 7.59237 
TARGETSEQUENCE193 TGC TGG CGGCCAGCTCCTGATGTTTC 7.57186 
TARGETSEQUENCE39 CGA CGG GCCGGCTTGCCCGATTTCCG 7.56243 
TARGETSEQUENCE109 AGT AGG CAAGGTCACCCTGGCTTACA 7.51026 
TARGETSEQUENCE17 AGC AGG TCGAGGCCGTCTCTATAAGT 6.3988 
 
 Table 1: 29 sgRNAs Have High Predicted Cleavage Efficiencies. 29 
putative sgRNAs have predicted efficiency scores above the high efficiency 
threshold of 7.5 according to the DRSC/TRiP CRISPR Efficiency Predictor tool. In 
addition, Target Sequence 17, an sgRNA designed as part of an older pipeline that 
did not take efficiency into account and did not mediate measurable gene knock-in 
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(data not shown), has a score of 6.3988, well below the high efficiency threshold. 
The six highest-scoring putative sgRNAs, hereafter referred to as sg1, sg2, sg3, sg4, 
sg5, and sg6 in order of decreasing efficiency score, were chosen to have their 
cleavage efficiencies evaluated in vitro. 
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DISCUSSION 
 The results here demonstrate the critical importance of incorporating sgRNA 
efficiency prediction and/or validation into sgRNA selection pipelines for any 
therapeutic modality involving personalized gene editing with CRISPR/Cas9. When 
efficiency is not taken into account, as was not the case with Target17 here, the 
likelihood of a sufficient number of editing events occurring to induce a phenotypic 
alteration or, presumably, a therapeutic response drops dramatically. Since both 
PCR and CRPG cleavage by B3Z-produced β-galactosidase are capable of massively 
magnifying small signals, it is highly unlikely that successful construct insertion and 
expression off that inserted construct occurred but was at too low of a level to be 
detected. 
 The immediate goal of this project moving forward will be to validate the 
cleavage efficiencies of sg1, sg2, sg3, sg4, sg5, and/or sg6. Once it has been 
demonstrated that neoPAMs are targetable with CRISPR/Cas9, designing a construct 
that can be used as a template in homologous recombination and can express 
SIINFEKL will be more of a technical challenge than a scientific one. 
  Therefore, the question of what effector polypeptide to express off the donor 
DNA construct is worth considering. Suicide genes seem the obvious candidate, as 
they are the best characterized and are capable of producing powerful bystander 
effects that can help overcome the low efficiency of any in vivo gene editing protocol. 
However, homologous recombination efficiency decreases markedly as insert size 
increases97. Because suicide genes tend to be large enzymes, any insert containing a 
suicide gene will be approaching the size limits of the CRISPR/Cas9 system. Thus, 
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the efficiency of suicide gene insertion may be too low to mediate a significant 
therapeutic effect, since small numbers of cells transfected will quickly be 
eliminated before they can generate enough toxic metabolites to exert a bystander 
effect. 
 Cytokines, in contrast, tend to be small genes that retain a potent antitumor 
effect when released intratumorally by broadly activating immune cells and 
promoting an inflammatory microenvironment. They are small enough that it may 
be possible to express multiple cytokines divided by self-cleaving peptides off a 
single promoter, thereby taking advantage of the combinatorial effects of multiple 
pro-inflammatory cytokines being released into the local milieu. In addition, 
because cytokines exert most of their cytotoxicity through immune cells that may or 
may not attack the cell from which the cytokines were initially secreted, these 
proteins are toxic to tumors overall but may not be as powerfully cytotoxic to 
individual cells. This effect, if real, may magnify the bystander effect by allowing 
cytokine-producing cells to remain in the tumor population longer. 
 B7 costimulatory ligands are also much smaller than suicide genes. Because 
their expression on tumor cells can permit naïve T cells to become primed by tumor 
cells directly without the need for an intermediary APC, they may be capable of 
unleashing powerful CTL- or NK cell-mediated responses that can go on to eradicate 
tumors locally and systemically. However, because they rely on CTLs and/or NK 
cells to mediate their antitumor effects (except for tumors with MHC Class II 
expression which can be controlled with CD4+ T cells alone), their insertion into 
tumor cells may only be effective for tumors with functional MHC Class I 
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presentation machinery. Further, because they are membrane-bound proteins, they 
likely will induce primed CTLs and activated NK cells to quickly and efficiently kill 
successfully edited tumor cells, severely limiting how many tumor-specific CTLs can 
be primed by a single B7 costimulatory ligand-expressing tumor cell. 
 The two most significant challenges facing any in vivo gene editing strategy 
are delivery and efficiency98. Techniques associated with Cas9 delivery are outside 
the current scope of this project and hence will not be discussed here. The problem 
of efficiency, however, is potentially tractable. Because the efficiency of gene knock-
in is inversely correlated with insert size, when choosing between two otherwise 
equivalently effective strategies, the one that involves a smaller insert should be 
chosen. More broadly, the problem associated with modifying tumor cells to express 
cytotoxic genes is that too few cells in the tumor may be modified to produce a 
bystander effect strong enough to destroy the tumor before the modified cells 
themselves are eliminated. In other words, modifying tumor cells to express 
cytotoxic genes produces a selective pressure that acts to remove those same tumor 
cells, thereby allowing the tumor to escape. A gene editing strategy that reversed the 
direction of the selective pressure to favor modified cells within the tumor might 
therefore overcome low insertion efficiency by gradually increasing the allele 
fraction of the modified locus in the tumor population. 
 There is, in fact, an analogous method used ubiquitously in molecular and 
cellular biology to purify strains with a desired modification – selection of antibiotic 
resistant clones. By linking the expression of a desired gene with an antibiotic 
resistance gene, antibiotic selection creates selective pressure to express the 
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desired gene. Thus, a construct that contains a resistance gene to a 
chemotherapeutic compound and a suicide gene that exerts cytotoxicity through a 
different mechanism than the chemotherapy might therefore enrich the tumor in 
cells expressing the suicide gene. Inducing the suicide gene in a tumor enriched in 
cells expressing the suicide gene would produce a significantly stronger bystander 
effect far more likely to be capable of completely destroying the tumor. 
(a) 
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(b) 
 
 Figure 6: Model for Combining Resistance and Suicide Genes in Single 
Constructs to Direct Tumor Evolution. (a) Two different constructs potentially 
capable of directing tumor evolution by simultaneously providing resistance to one 
cytotoxic agent and sensitizing tumor cells to another are shown. The order of these 
genes in the construct is likely not relevant. These proteins could be expressed off 
the same promoter by linking the polypeptides with self-cleaving viral 2A 
peptides99,100 or internal ribosome entry site (IRES) elements101,102. (b) At first, not 
many cells in a tumor are successfully edited. After the induction of the suicide gene 
to which resistance has been provided or the start of chemotherapy, cells expressing 
polypeptides from the construct grow unabated while the growth of unedited cells 
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is significantly inhibited. Once a sufficient proportion of the tumor contains the 
construct, the second suicide gene is induced, producing an overwhelming 
bystander effect that wipes out the tumor. 
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FUTURE DIRECTIONS 
 The most immediate priority is validating the cleavage efficiency of the six 
sgRNAs with the highest predicted cleavage efficiency. Cleavage efficiency validation 
will also be repeated with Target17 (sg7) to confirm it is inefficient, as the positive 
control cleavage band intensity was lower than expected. Once cleavage efficiency 
has been validated for the six sgRNAs, the highest efficiency sgRNA will be ordered. 
New homology arms will be identified from the sequences flanking the target site in 
the mm10 reference genome and used to design new donor DNA sequences as 
previously described. 
 The ability of these donor DNA constructs to generate SIINFEKL that can be 
presented on the FABF cell surface will be assayed as previously described and 
compared. Once the best donor DNA construct has been identified, the ability of 
edited FABF cells to elicit anti-SIINFEKL responses in vivo will be investigated. The 
magnitude of the bystander effect whereby anti-SIINFEKL responses lead to a 
generalized antitumor immune response will be quantified. These experiments will 
be repeated in a different tumor cell line that does not contain the targeted neoPAM 
to demonstrate that the editing event is truly restricted to cells harboring the 
mutation. 
 After demonstrating the effectiveness of neoPAM knock-in by inserting a 
SIINFEKL-producing construct into FABF, multiple different antitumor strategies 
outlined above will be investigated. In particular, TK007 and a bicistronic construct 
expressing interferon-γ and IL-2 will be knocked into tumor cells separately. Bulk 
edited cells will be used to form tumors in mice and their growth will be monitored 
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to assess the magnitude of the constructs’ antitumor effects. Finally, a polycistronic 
construct will be generated that will express cytosine deaminase, the 5-FU 
metabolizing enzyme DPYD103, and TK007. These cells will be used to form tumors 
in mice that will be treated with first with 5-FC and later with ganciclovir. 
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APPENDIX I: PREDICTED GUIDE RNA EFFICIENCIES OF TARGETABLE SNVS IN 
FABF EXOME 
Identifier Wild 
Type 
PAM 
NeoPAM Target Sequence Predicted 
Efficiency 
TARGETSEQUENCE122 CAG CGG CAAGTTCAACGTGTGGGACA 9.0919 
TARGETSEQUENCE11 AGA AGG GAGGCCAGCCTGGTCTATAG 9.07017 
TARGETSEQUENCE29 TAG TGG CATCGCCAACTTCTCTGAGC 8.96595 
TARGETSEQUENCE47 TGA TGG TCATGCAGGCATCCGACGAG 8.90553 
TARGETSEQUENCE8 TTG TGG TCTCTATACCACTTCTCTAC 8.70791 
TARGETSEQUENCE97 GAG GGG CGGCTGCGGCGAGCGGGGAG 8.67553 
TARGETSEQUENCE209 GGT GGG TGCCGGCGACGGCTGGGTAT 8.61632 
TARGETSEQUENCE15 CCG CGG AGAGTCCTGCCGCTTCAAGG 8.55223 
TARGETSEQUENCE202 TGC TGG GTCCAAGAGCATGCAGTGAC 8.42117 
TARGETSEQUENCE60 CGA CGG TTCTGGGGTCTGATGAGCGT 8.25255 
TARGETSEQUENCE172 CTG CGG GTTTCCCGGAAGCTGCCCGG 8.17607 
TARGETSEQUENCE134 TTG TGG TGATGTTTCCAGTTATTTAT 8.15388 
TARGETSEQUENCE87 CTG CGG GGCGTCCCGCGGGCCGGCGC 8.14489 
TARGETSEQUENCE115 GGC GGG TGGAGGCTGCACAGTGCACA 8.12777 
TARGETSEQUENCE113 GTG GGG TTTTTTTGGTGTGTGTGTGT 8.10467 
TARGETSEQUENCE61 TTG TGG CTATGCTTACTGTTCTGTTT 8.08406 
TARGETSEQUENCE64 TGC TGG TGAAGAGGTCGTGGGGAATG 7.98259 
TARGETSEQUENCE168 CAG CGG ATTCCCAAGCAATCCGACTC 7.97552 
TARGETSEQUENCE111 AGA AGG GGAGCCTTCCTCTTTCTGTT 7.90524 
TARGETSEQUENCE31 CAG CGG CCAGGACTGAGCCTGGGGAC 7.90438 
TARGETSEQUENCE25 CAG CGG ACATCCATGGAGCTGTCAGC 7.88473 
TARGETSEQUENCE152 AGC AGG ACAGGGAAGTGCCTGTCGTG 7.82484 
TARGETSEQUENCE138 CTG CGG CGCCAGAAGCGAGAGCCCCT 7.8206 
TARGETSEQUENCE46 CAG CGG GCAGTTAAACATGGGTCAGT 7.78494 
TARGETSEQUENCE114 AGA AGG CTTTCAGAACGGGACCGCCG 7.59664 
TARGETSEQUENCE49 CGC CGG GGTGGAAGGCCACGAGCGCT 7.59237 
TARGETSEQUENCE193 TGC TGG CGGCCAGCTCCTGATGTTTC 7.57186 
TARGETSEQUENCE39 CGA CGG GCCGGCTTGCCCGATTTCCG 7.56243 
TARGETSEQUENCE109 AGT AGG CAAGGTCACCCTGGCTTACA 7.51026 
TARGETSEQUENCE48 AGT AGG TTCCATGGACCGATGGACTG 7.49501 
TARGETSEQUENCE165 GCG GGG CACGAGCGGCGCCGGGGAGT 7.48202 
TARGETSEQUENCE118 GGC GGG AAGACAAGGGCTCTGATGGG 7.47718 
TARGETSEQUENCE28 GGA GGG GTCCTGTTCCCATTGATGGT 7.35056 
TARGETSEQUENCE184 AGC AGG AGCAAGCAGCCTACCAGGCT 7.329 
TARGETSEQUENCE207 AGA AGG TGGACAGTGGCCATGGAAGT 7.31052 
TARGETSEQUENCE18 TGT TGG CATGGAAGACTCGATGGATA 7.24548 
TARGETSEQUENCE99 TTG TGG TCTGTTGGCCGAGGTGAGTC 7.21284 
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TARGETSEQUENCE179 AGC AGG CATACCAGGCTTTGAAAGGC 7.18283 
TARGETSEQUENCE176 TGA TGG CCTCCTGTTATTATGGGGTC 7.17312 
TARGETSEQUENCE86 CGT CGG GGGGTGGGGGGTGGGGGACC 7.16004 
TARGETSEQUENCE57 CCG CGG GGCAAGAAGCGCAAGCGCAG 7.14979 
TARGETSEQUENCE7 TGC TGG ACAAGTGTACTAGCAGTCTG 7.13917 
TARGETSEQUENCE90 CTG CGG CTAGGCATTCCTCCCTCCCT 7.13758 
TARGETSEQUENCE12 GTG GGG CTCTGGAGGACAGTCCATCA 7.12872 
TARGETSEQUENCE27 AGC AGG CATGGTCTCCAGCCTGGCCC 7.10614 
TARGETSEQUENCE100 GGC GGG GGGCGGGCGGAGGCCGCAGC 7.0806 
TARGETSEQUENCE156 TGT TGG CTTCCGGCTCTCTACATGCT 7.04131 
TARGETSEQUENCE131 AAG AGG CCACCAAGTCACGCACCAAA 7.01241 
TARGETSEQUENCE162 CGC CGG TCCCGTGGCCATCATACCCC 6.99684 
TARGETSEQUENCE145 TGC TGG TTGCTAATTACCGTCTCTTC 6.98089 
TARGETSEQUENCE91 CAG CGG CGCTGGCAGAACGAGAAGAG 6.96332 
TARGETSEQUENCE82 AGC AGG TTCTCCCCGATGCTGGACAC 6.95848 
TARGETSEQUENCE101 GGA GGG CCGGGGACGGAGGGGAGAGC 6.90135 
TARGETSEQUENCE70 TGC TGG GCTCTCCTCGGGGTCAATGA 6.85213 
TARGETSEQUENCE20 CAG CGG GAGCCAGGGATAATCTGAGT 6.84996 
TARGETSEQUENCE53 AGC AGG TTCTTCTTTGATTTCTTTTC 6.81477 
TARGETSEQUENCE112 GGC GGG GAAGCGGCCCATAAAGGGGG 6.81466 
TARGETSEQUENCE85 GGA GGG GTGGGGGACCCGTCGTCTGT 6.77051 
TARGETSEQUENCE169 GGA GGG GCTCGGCTCTTCCTGGAGTC 6.74216 
TARGETSEQUENCE79 AAG AGG TCTGTTACGCAGAGTTAAGA 6.73532 
TARGETSEQUENCE35 ATG AGG GCACGCACACAGTCCATGGC 6.73034 
TARGETSEQUENCE208 CAG CGG AGTTGTTACACACTCCTTAG 6.69514 
TARGETSEQUENCE158 TTG TGG TATTAAGATGGTCTCCCAGC 6.68536 
TARGETSEQUENCE30 AGC AGG ACCTTATCCCCAGGCGGAAC 6.67683 
TARGETSEQUENCE210 CAG CGG TGGAGCGTGGGGACCATACC 6.57391 
TARGETSEQUENCE181 TTG TGG CATTATCTGCCCTAAGATGT 6.54838 
TARGETSEQUENCE124 CAG CGG CTGGTGGGCGACGGCAGCAC 6.52535 
TARGETSEQUENCE155 CCG CGG CGAGGAGCCCGACCTCCCCC 6.51818 
TARGETSEQUENCE10 AAG AGG AAGTGGATCTGGCTGAAGTG 6.49663 
TARGETSEQUENCE175 CTG CGG GTCACTGTCGCCTTGATTTC 6.49193 
TARGETSEQUENCE201 GGC GGG TCCCTCCTCAGGGTTCCCCT 6.48417 
TARGETSEQUENCE133 CAG CGG AACGGAATGGATGAAGGTTA 6.48375 
TARGETSEQUENCE166 CAG CGG GGCGCGCCGGGGGCCGCGAC 6.47819 
TARGETSEQUENCE105 GTG GGG CCGTGTCCCCGCCGCCGCCA 6.46101 
TARGETSEQUENCE38 GAG GGG AGTCGCCCAAGAGGGCTGAG 6.43311 
TARGETSEQUENCE17 AGC AGG TCGAGGCCGTCTCTATAAGT 6.3988 
TARGETSEQUENCE40 AGA AGG AACCCGCGACCGGCACCGAC 6.36686 
TARGETSEQUENCE192 CGA CGG TGCGGCGACCGCTCTTGTGA 6.35608 
TARGETSEQUENCE147 GGA GGG CGTGGCGGCGCTGCTGGCCG 6.34633 
TARGETSEQUENCE174 AGC AGG GTACTGGTTTTCCTCCCAGC 6.31684 
TARGETSEQUENCE76 CAG CGG GGGAGACTGAGGGCCCGGCC 6.28109 
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TARGETSEQUENCE62 CTG CGG AATGCAGCATCTGCGATGTG 6.25101 
TARGETSEQUENCE203 GGC GGG GTCACTAGGGATGCAATGGG 6.23212 
TARGETSEQUENCE160 CAG CGG TTTCCCATGAACAAAAGAAC 6.22627 
TARGETSEQUENCE4 TTG TGG CATCCACTTCCTTCAGTGTA 6.22058 
TARGETSEQUENCE66 AAG AGG ACCTGAAACCCCAAAGCAAA 6.20832 
TARGETSEQUENCE173 TTG TGG GTAGCCTCTTGCATCAGCTC 6.18684 
TARGETSEQUENCE65 AAG AGG TGAGAACCAACTTTCCCAAC 6.18632 
TARGETSEQUENCE125 CAG CGG CTCGTCCTGGTGGGCGACGG 6.17893 
TARGETSEQUENCE96 CGC CGG GGGGCCGTCGTGTTTCGGGT 6.12515 
TARGETSEQUENCE80 CAG CGG GCTCTAAGGGCTGGGTCTGA 6.12091 
TARGETSEQUENCE13 CCG CGG TGAGTGTCCCATCCTGAGCT 6.11728 
TARGETSEQUENCE44 CAG CGG CAAGGCACGTGCCCCTCTCT 6.09946 
TARGETSEQUENCE170 CTG CGG TGAAACCGTTAAGAGGTAAA 6.0761 
TARGETSEQUENCE144 GGC GGG CTCACTAGTCTTCCCCAAGT 6.06224 
TARGETSEQUENCE83 CCG CGG GCATGACTGGAGAGGCCAGC 6.05279 
TARGETSEQUENCE204 ACG AGG CAGCGTGCACTGAAAAGAGG 6.02901 
TARGETSEQUENCE187 TAG TGG TTCTTCCTCTTCATTCGCCC 5.99791 
TARGETSEQUENCE127 CGC CGG AAGGACTCCTGCTTCTGCTT 5.9431 
TARGETSEQUENCE129 CAG CGG CGCGGCCCGGACCGTCGCGG 5.9013 
TARGETSEQUENCE69 CAG CGG GCCACCTCCATCTTGTTGTG 5.88761 
TARGETSEQUENCE74 ATG AGG TTAATGAGCCTCCGAAGAGT 5.86874 
TARGETSEQUENCE58 AGC AGG ACTTCTTGGAACAATGTGTC 5.85862 
TARGETSEQUENCE67 AGC AGG CCAGTTTAAGAGTTGGGTGA 5.78629 
TARGETSEQUENCE183 TCG TGG TAGGTGGAAGTCTTCTACTC 5.77796 
TARGETSEQUENCE81 GCG GGG GTAGATGGACCGAAGGATCA 5.74471 
TARGETSEQUENCE104 GAG GGG ACACACAAGACGGGGAGAGC 5.71338 
TARGETSEQUENCE77 CTG CGG CACGTCTGAACTTTGGGAGA 5.70015 
TARGETSEQUENCE6 TAG TGG CTGCAATCAGCACTGGCTCT 5.67779 
TARGETSEQUENCE199 AAG AGG TGTTGGTTGATATAGACAGC 5.62602 
TARGETSEQUENCE157 CTG CGG TTTGAGTTTGCTGGGGGAAG 5.62123 
TARGETSEQUENCE45 CAG CGG CGGGTTCAGATCCCCAAATC 5.5684 
TARGETSEQUENCE102 CAG CGG CGGGTTTTGTCGGACCCCGA 5.5511 
TARGETSEQUENCE23 CGC CGG AGCTCTTACCGTTGTCACAC 5.53652 
TARGETSEQUENCE151 TCG TGG AAAGGACAGGGAAGTGCCTG 5.52926 
TARGETSEQUENCE191 CCG CGG CGAAGTTGGTGGGGAAAAAG 5.52594 
TARGETSEQUENCE185 CTG CGG GGCAGCTACTCTCTTCACAT 5.49995 
TARGETSEQUENCE136 CAG CGG AACGGGCTTGGCGGAATCAG 5.44758 
TARGETSEQUENCE188 CAG CGG CCTGAGTTCGTAGGCGCAGC 5.43718 
TARGETSEQUENCE182 TGC TGG CATCTTGGCTCCGCTCTGAC 5.37512 
TARGETSEQUENCE68 TGA TGG CTGCTCCTCGTCTCGGCCTC 5.25009 
TARGETSEQUENCE132 CCG CGG GAAGACGGGTCAGCTGAGGT 5.21881 
TARGETSEQUENCE72 ATG AGG TCATGGCGCACAGCCTCTGG 5.21703 
TARGETSEQUENCE200 GGA GGG AGGAAGTCTCTTTAAGAAAA 5.20918 
TARGETSEQUENCE205 AAG AGG CTTTCCCTTTTTTCCAAAGG 5.2061 
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TARGETSEQUENCE141 GGC GGG TAGGCAGAATTTGCTCCCCT 5.1969 
TARGETSEQUENCE51 TCG TGG CGTGCATGAGAAAAGAGCCG 5.18665 
TARGETSEQUENCE56 CGC CGG TTTGAGGACACCAACCTGTG 5.13792 
TARGETSEQUENCE164 ACG AGG GGCGGTCTTGGCCAGGTGGC 5.13594 
TARGETSEQUENCE5 GGA GGG AACCATGCGGTAGCTCTTGC 5.13309 
TARGETSEQUENCE78 TGT TGG CGGGAAAACGCAGGGTTGTA 5.13107 
TARGETSEQUENCE110 AGC AGG TGTGGCGTTATGTATACTAA 5.12674 
TARGETSEQUENCE137 GAG GGG CCGACCCCGACGCGAGGACG 5.11605 
TARGETSEQUENCE161 CCG CGG TCTGAAGCAGATAGACCAGG 5.08964 
TARGETSEQUENCE94 CTG CGG GAACTCGGAGCGGGGAGGCG 5.08578 
TARGETSEQUENCE36 ACG AGG GTCCCCAGGTTCCCAGGGTC 5.0781 
TARGETSEQUENCE92 GGA GGG CGGAGGCACACCAGGGAATG 5.0759 
TARGETSEQUENCE98 GAG GGG GGTCAGTCAGAGGAGAGGGG 5.06516 
TARGETSEQUENCE143 CAG CGG CCCAGAAAGGCAACGTGACT 5.06346 
TARGETSEQUENCE108 TAG TGG TTCAGTCATAATCCCACAGA 5.02782 
TARGETSEQUENCE189 CCG CGG AGGAATGCCAGTCGCAGCTG 5.01306 
TARGETSEQUENCE128 CAG CGG GGGGGCATCGGCAGAAGGGG 5.00173 
TARGETSEQUENCE153 TGC TGG ATGGTTCCGATGCCCCACAT 4.98881 
TARGETSEQUENCE89 AGA AGG AGCGGCCGCGTGCGGCGCAA 4.93993 
TARGETSEQUENCE171 CAG CGG AACGATGCCGACTGGTGATG 4.89998 
TARGETSEQUENCE194 AAG AGG TTCAGCTCATACTCGGGTGG 4.89753 
TARGETSEQUENCE34 CGC CGG GAACTCCTCGAAGCCCAGCA 4.89131 
TARGETSEQUENCE54 CCG CGG GCTCCTGCGACCTGCTGCTA 4.82327 
TARGETSEQUENCE148 CAG CGG CACCTAGTGGTGACAAGTTT 4.80408 
TARGETSEQUENCE52 AGC AGG CTTCTTCTATTTCCTTTTCC 4.77708 
TARGETSEQUENCE32 GCG GGG TTACCATCACCATCGGAGCA 4.77594 
TARGETSEQUENCE146 CCG CGG CTAGAAGCAAGTGAAGCCGA 4.75457 
TARGETSEQUENCE135 GGT GGG GAGAAAGACATAGATGTGCC 4.73426 
TARGETSEQUENCE71 CCG CGG GCCACCTCTTCTGCCTGCAG 4.72597 
TARGETSEQUENCE21 CGC CGG GACACACTGAAGTCCAAGTA 4.72112 
TARGETSEQUENCE139 GGC GGG AGAGGGGAAGAGTAGAAAGA 4.71344 
TARGETSEQUENCE19 AAG AGG GGAAAGCGATCTGCTCCTGG 4.70543 
TARGETSEQUENCE163 CTG CGG CTGGTCGTTGCGACTTCGTC 4.6899 
TARGETSEQUENCE24 TGC TGG GGATATGCAGGAGCTGGAAG 4.68434 
TARGETSEQUENCE59 AGA AGG CTTCTACTATGACCAGTGCG 4.67399 
TARGETSEQUENCE149 AGC AGG ACCTAGTGGTGACAAGTTTC 4.65943 
TARGETSEQUENCE197 TGA TGG ATTTTCACAGCTAGTTGATT 4.65266 
TARGETSEQUENCE121 AGC AGG GTCTCTCCCTGGGGACTCCG 4.62262 
TARGETSEQUENCE117 AAG AGG ACCATACACTCATTAAAAGA 4.60744 
TARGETSEQUENCE93 TCG TGG GTCTCTCCCGAATGGTCCCC 4.60179 
TARGETSEQUENCE42 AGC AGG CCCTTGAAAATCCGGGGGAG 4.58036 
TARGETSEQUENCE22 TTG TGG GCGCATTTTTGTGGTGGGTT 4.50944 
TARGETSEQUENCE107 CAG CGG GAGCTTTGGAAATCCCAGCG 4.49144 
TARGETSEQUENCE167 GGC GGG GCCCCCGGCGCGCCGGGCTC 4.46064 
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TARGETSEQUENCE154 GGT GGG CACATGAACGGGCGGTCTCC 4.44428 
TARGETSEQUENCE73 TGC TGG ATGATGGTTTTCCGAAGCTT 4.43532 
TARGETSEQUENCE130 CCG CGG CACCCACTCTCTCGCTGCTC 4.43252 
TARGETSEQUENCE177 CGC CGG AGGTTTTTCTCCGATTCAGA 4.43023 
TARGETSEQUENCE195 AGC AGG GCTCGTGGAAGATGTCTTCC 4.4277 
TARGETSEQUENCE9 TGA TGG GGCCAGTGTCCCTCTCACAC 4.42154 
TARGETSEQUENCE95 AAG AGG CACGGACCCTCTCGACCCCG 4.37757 
TARGETSEQUENCE26 TGA TGG AGCCTGACCTCCCAGGAGAG 4.33787 
TARGETSEQUENCE159 TGC TGG GGGAGATGGGGCCCAAATCA 4.33521 
TARGETSEQUENCE41 CCG CGG GGTTCGGGAGCGGAAAAAGA 4.31398 
TARGETSEQUENCE190 GCG GGG CTCCTTGATGGCTGGTGTAA 4.31297 
TARGETSEQUENCE178 GCG GGG ACCTTCTTCACCCAGCCTAA 4.31239 
TARGETSEQUENCE33 TCG TGG GAGAGCCTTGGGCACCAGAA 4.25377 
TARGETSEQUENCE84 GGC GGG CTGTGGATTGTGCGTCCCGG 4.24152 
TARGETSEQUENCE150 TGA TGG CAAAGCTCCTGGTCCCCGGT 4.23858 
TARGETSEQUENCE43 CGT CGG CCATGACGCTTTCCAAGGCA 4.22658 
TARGETSEQUENCE180 TCG TGG GGATCCCGTACTTCTCCAGC 4.20347 
TARGETSEQUENCE1 TGA TGG GAATAACATTGAGAATTTAA 4.20293 
TARGETSEQUENCE119 TGC TGG CCAGCCTGAGAGTATCTCCC 4.15624 
TARGETSEQUENCE103 CAG CGG AACGGGAGAGTGCATGCGGC 4.12085 
TARGETSEQUENCE37 TGC TGG AAGCCTGCAGTGAACCTCCA 4.06205 
TARGETSEQUENCE196 CAG CGG TCCAGCACCATCCATTTTCA 4.0254 
TARGETSEQUENCE14 TGC TGG GGCCAGCCAGGGAGGCTCCC 4.00327 
TARGETSEQUENCE123 TAG TGG GAACTTGATGGGTCCTCTGT 3.93871 
TARGETSEQUENCE126 CGC CGG GTGATTCCCATCAAAAGTGC 3.9386 
TARGETSEQUENCE63 CAG CGG TGTCTTTTTGGATGGCGTCA 3.92324 
TARGETSEQUENCE120 CCG CGG TCCCCCTCCTCCACGTGAGT 3.88766 
TARGETSEQUENCE140 TGA TGG GTGGGTGATGTCTGTGAAGA 3.84887 
TARGETSEQUENCE198 TGT TGG GGTTGATATAGACAGCAAGA 3.77935 
TARGETSEQUENCE116 TAG TGG ATGCTCCCTTCCCCTTACTG 3.76858 
TARGETSEQUENCE88 GGC GGG CAGAGATGAAGAAAAGCCAA 3.76649 
TARGETSEQUENCE106 ATG AGG GCTTCTTATACTTGAGGTCC 3.75764 
TARGETSEQUENCE75 GAG GGG TGGTGAACTATGCCTGGGCA 3.72089 
TARGETSEQUENCE142 CAG CGG TAGTCTGGTGCTTCTGAGGC 3.68784 
TARGETSEQUENCE2 AAG AGG TGGCTTTAATCTCCTTCAGC 3.64992 
TARGETSEQUENCE186 TGC TGG TCCCAGGCTGGGAGTCCCAT 3.64314 
TARGETSEQUENCE16 CCG CGG GCCAATGGTGCCAGAATTCA 3.54109 
TARGETSEQUENCE3 TAG TGG GGAATTGAATGAACACAGCC 3.4996 
TARGETSEQUENCE55 CAG CGG GCAGAACTTATTTGAGAGGC 3.43438 
TARGETSEQUENCE50 AAG AGG AAAAAAAAAATCCAAAGCCG 3.33545 
TARGETSEQUENCE206 CAG CGG TAAAAATCATTAAAAATGGA 2.67133 
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APPENDIX II: DONOR DNA, SGRNA, AND PRIMER SEQUENCES 
ER Insert: 
 
>5' homology arm (482) 
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC 
 
>CMV enhancer (304) 
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG 
 
>CMV promoter (204) 
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT 
 
>Kozak sequence (9) 
GCCGCCACC 
 
>E3/19K ER insertion signal with N-terminal Met (51) 
ATGAGGTACATGATCCTGGGCCTGCTGGCCCTGGCCGCCGTGTGCAGCGCC 
 
>SIINFEKL (24) 
AGCATCATCAACTTCGAGAAGCTG 
 
>Stop codon (3) 
TGA 
 
>SV40 PolyA Signal (122) 
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA 
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>3' homology arm (424) 
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG 
 
 
Spacers: 
 
>5' homology arm (482) 
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC 
 
>CMV enhancer (304) 
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG 
 
>CMV promoter (204) 
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT 
 
>Kozak sequence (9) 
GCCGCCACC 
 
>SIINFEKL plus spacer (102) 
ATGGCCGTGCTGCTGCCCGACGAGGTGAGCGGCCTGGAGCAGCTGGAGAGCATCATCAAC
TTCGAGAAGCTGACCGAGTGGACCAGCAGCAACGTGATGGAG 
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>Stop codon (3) 
TGA 
 
>SV40 PolyA Signal (122) 
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA 
 
>3' homology arm (424) 
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG 
 
 
TruncOVA: 
 
>5' homology arm (482) 
GTTACCAGGCTATCCCTAGACCTTGCCATAACTCCTGGCACATAGGGGATGCTCACACAA
GCCTATTAACTTTGTAAAGCAAAATTTCATGGGACGTTTCATAATGTGAATTTCTCCTA
AAATAAGTCAGAAGCAAAACCAGCAAAAGAGGCAGCATTTCTTTATTACCTGCAATTAG
TCATTTGCATGGTACAAAGAGGTGAAAAGTTTCAGATACATGATTTGGATGAATTGATT
TTTAAAGATTTTACTTTTATTATTTTTACTGTGTGTGTGCATACATGTGTGTGTATGCAC
TCCTGTGCATGTGTGTGCACACACAGGCACCTACTTGAGTATAGGTGCCTACAAAATCTG
GAAGACAACACTGGATTCCTGGTAGCTGGAATCACCGAAGGCTGTGATACAGGTGCTGG
GGAGTCCTTTACCAATGAGCTGCATCTCAGGATCTGGGGCACGCCTTCTCACAGAGGACA
CTGTCC 
 
>CMV enhancer (304) 
CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATT
GACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCA
ATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCC
AAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTA
CATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC
CATG 
 
>CMV promoter (204) 
GTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATT
TCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAATCAACGGGA
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CTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACG
GTGGGAGGTCTATATAAGCAGAGCT 
 
>Kozak sequence (9) 
GCCGCCACC 
 
>Truncated Ovalbumin (864) 
ATGGGCAGCCTGGCCAGCAGACTGTACGCCGAGGAGAGATACCCCATCCTGCCCGAGTAC
CTGCAGTGCGTGAAGGAGCTGTACAGAGGCGGCCTGGAGCCCATCAACTTCCAGACCGCC
GCCGACCAGGCCAGAGAGCTGATCAACAGCTGGGTGGAGAGCCAGACCAACGGCATCATC
AGAAACGTGCTGCAGCCCAGCAGCGTGGACAGCCAGACCGCCATGGTGCTGGTGAACGCC
ATCGTGTTCAAGGGCCTGTGGGAGAAGGCCTTCAAGGACGAGGACACCCAGGCCATGCCC
TTCAGAGTGACCGAGCAGGAGAGCAAGCCCGTGCAGATGATGTACCAGATCGGCCTGTTC
AGAGTGGCCAGCATGGCCAGCGAGAAGATGAAGATCCTGGAGCTGCCCTTCGCCAGCGGC
ACCATGAGCATGCTGGTGCTGCTGCCCGACGAGGTGAGCGGCCTGGAGCAGCTGGAGAGC
ATCATCAACTTCGAGAAGCTGACCGAGTGGACCAGCAGCAACGTGATGGAGGAGAGAAA
GATCAAGGTGTACCTGCCCAGAATGAAGATGGAGGAGAAGTACAACCTGACCAGCGTGC
TGATGGCCATGGGCATCACCGACGTGTTCAGCAGCAGCGCCAACCTGAGCGGCATCAGCA
GCGCCGAGAGCCTGAAGATCAGCCAGGCCGTGCACGCCGCCCACGCCGAGATCAACGAGG
CCGGCAGAGAGGTGGTGGGCAGCGCCGAGGCCGGCGTGGACGCCGCCAGCGTGAGCGAGG
AGTTCAGAGCCGACCACCCCTTCCTGTTCTGCATCAAGCACATCGCCACCAACGCCGTGCT
GTTCTTCGGCAGATGCGTGAGCCCC 
 
>Stop codon (3) 
TGA 
 
>SV40 PolyA Signal (122) 
AACTTGTTTATTGCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCAC
AAATAAAGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAATGTATC
TTA 
 
>3' homology arm (424) 
GGTTTCTGATGTACTCCCGGTACATGGCAGTGTCCTCTTTGCCAAGGGGCTGCATGATAC
CTTGGCTAGCTTGGATATGGGCCTGGAAGATCTCTGTAGACTTTCTGTCTACTCTTGGAG
GCTGAACTTCATAAATGTTGTCTTGCGAGAAAGCTGAGATGGGAGTTCTGTAAAAGAGG
AAAGACAGGACTGTGTTATGGAACTTCTCACCACAACATGGGCTTCACCAACCAAGGGCA
ACCTCTGCAGTTGTTACTTCCTGGGAGGCCAAAGGATAGAAGCTGTCCCTGATACCCAGG
CAGGGCAGAGGTCCTGTCCCTTATAGAATGTCAGCTCTATAGTTGCGTGTCCTGCTGGCT
CCCACTGGAAGAAGCTTCAGGTGGTACTATACCTAAGTTTTGTTCCTTGTCCTTGCAGGC
TCTTG 
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sgRNAs: 
sgRNA Name Target Sequence NeoPAM 
sg1 CAAGTTCAACGTGTGGGACA CGG 
sg2 GAGGCCAGCCTGGTCTATAG AGG 
sg3 CATCGCCAACTTCTCTGAGC TGG 
sg4 TCATGCAGGCATCCGACGAG TGG 
sg5 TCTCTATACCACTTCTCTAC TGG 
sg6 CGGCTGCGGCGAGCGGGGAG GGG 
sg7 TCGAGGCCGTCTCTATAAGT AGG 
 
 
Primers: 
Experiment  Forward Primer Reverse Primer 
Donor DNA 
Amplification 
(Fig. 4a) 
GGGTGGCCTATGGAGGT CAAGAGCCTGCAAGGACAA 
SIINFEKL-
Specific 
Amplification 
(Fig. 4b) 
GTGATGCGGTTTTGGC GTGATGCTATTGCTTTATTTGTAACC 
Cleavage 
Validation 
(sg1) 
GTATGTAGCCACCCTGGG GGCAACAAACTCCAAGTTAGG 
Cleavage 
Validation 
(sg2) 
TAATAGGTCGCCGGGC TCAGGTCTTAGCAAATGCAA 
Cleavage 
Validation 
(sg3) 
GGATACCAGACACCGTGAAC GCCCCTCTGAATCACATC 
Cleavage 
Validation 
(sg4) 
GCTGAAGCCCAGCAAAGA TGACGCTTTCCAAGGCA 
Cleavage 
Validation 
(sg5) 
TACACATCGACAGCCCAA GCACAAGAACAGGACACACT 
Cleavage 
Validation 
(sg6) 
TTCCCGAAGGACGACAG CAGTGTGATTCCCGCC 
Cleavage 
Validation 
(sg7) 
CCGAAGGCTGTGATACAGG GCTTCTTCCAGTGGGAGC 
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